source
- Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next yearInhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…
- Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancerInhibrx announced that its experimental immunotherapy targeting the protein OX40 produced measurable responses in patients with head and neck cancer, with the clearest activity observed in a small…